MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP - Toronto Stock Exchange - CA58410Q2036 - Common Stock - Currency: CAD
MDP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. MDP has an average financial health and profitability rating. MDP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
MDP had positive earnings in the past year.
In the past year MDP had a positive cash flow from operations.
MDP had negative earnings in 4 of the past 5 years.
In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
MDP has a better Return On Assets (2.44%) than 84.38% of its industry peers.
Looking at the Return On Equity, with a value of 10.76%, MDP belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
The Return On Invested Capital of MDP (13.60%) is better than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.44% | ||
| ROE | 10.76% | ||
| ROIC | 13.6% |
ROA(3y)-0.48%
ROA(5y)-5.11%
ROE(3y)-3.82%
ROE(5y)-38.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 3.25%, MDP belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
The Operating Margin of MDP (13.73%) is better than 81.25% of its industry peers.
With a decent Gross Margin value of 52.45%, MDP is doing good in the industry, outperforming 78.13% of the companies in the same industry.
In the last couple of years the Gross Margin of MDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 3.25% | ||
| GM | 52.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-2.29%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDP is creating some value.
MDP has more shares outstanding than it did 1 year ago.
MDP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MDP has an improved debt to assets ratio.
2.2 Solvency
MDP has an Altman-Z score of 0.83. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.83, MDP is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
MDP has a debt to FCF ratio of 1.95. This is a very positive value and a sign of high solvency as it would only need 1.95 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.95, MDP belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
MDP has a Debt/Equity ratio of 0.67. This is a neutral value indicating MDP is somewhat dependend on debt financing.
MDP has a worse Debt to Equity ratio (0.67) than 68.75% of its industry peers.
Although MDP does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.67 | ||
| Debt/FCF | 1.95 | ||
| Altman-Z | 0.83 |
ROIC/WACC1.56
WACC8.72%
2.3 Liquidity
MDP has a Current Ratio of 1.01. This is a normal value and indicates that MDP is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.01, MDP is not doing good in the industry: 78.13% of the companies in the same industry are doing better.
MDP has a Quick Ratio of 1.01. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MDP's Quick ratio of 0.49 is on the low side compared to the rest of the industry. MDP is outperformed by 71.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.49 |
3. Growth
3.1 Past
The earnings per share for MDP have decreased strongly by -53.33% in the last year.
MDP shows a decrease in Revenue. In the last year, the revenue decreased by -5.34%.
Measured over the past years, MDP shows a very strong growth in Revenue. The Revenue has been growing by 27.27% on average per year.
EPS 1Y (TTM)-53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
Revenue 1Y (TTM)-5.34%
Revenue growth 3Y12.38%
Revenue growth 5Y27.27%
Sales Q2Q%18.96%
3.2 Future
The Earnings Per Share is expected to grow by 131.62% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 6.71% on average over the next years.
EPS Next Y651.46%
EPS Next 2Y-211.38%
EPS Next 3Y240.19%
EPS Next 5Y131.62%
Revenue Next Year-4.03%
Revenue Next 2Y-5.31%
Revenue Next 3Y2.37%
Revenue Next 5Y6.71%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.63, the valuation of MDP can be described as correct.
Based on the Price/Earnings ratio, MDP is valued cheaply inside the industry as 90.63% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 24.12. MDP is valued slightly cheaper when compared to this.
The Forward Price/Earnings Ratio is negative for MDP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.63 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDP is valued cheaper than 93.75% of the companies in the same industry.
MDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDP is cheaper than 96.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.96 | ||
| EV/EBITDA | 4.34 |
4.3 Compensation for Growth
MDP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MDP's earnings are expected to grow with 240.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y-211.38%
EPS Next 3Y240.19%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (5/7/2025, 7:00:00 PM)
2.59
-0.06 (-2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.93%
Inst Owner ChangeN/A
Ins Owners7.34%
Ins Owner ChangeN/A
Market Cap83.55M
Analysts80
Price Target6.24 (140.93%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.13%
Min EPS beat(2)-100%
Max EPS beat(2)69.73%
EPS beat(4)3
Avg EPS beat(4)79.07%
Min EPS beat(4)-100%
Max EPS beat(4)248.52%
EPS beat(8)5
Avg EPS beat(8)111.57%
EPS beat(12)7
Avg EPS beat(12)71.36%
EPS beat(16)8
Avg EPS beat(16)-278.5%
Revenue beat(2)1
Avg Revenue beat(2)3.22%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)6.82%
Revenue beat(4)2
Avg Revenue beat(4)0.71%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)6.82%
Revenue beat(8)4
Avg Revenue beat(8)-0.97%
Revenue beat(12)7
Avg Revenue beat(12)1.38%
Revenue beat(16)8
Avg Revenue beat(16)-6.13%
PT rev (1m)0%
PT rev (3m)-2.06%
EPS NQ rev (1m)-3.62%
EPS NQ rev (3m)-24.35%
EPS NY rev (1m)0%
EPS NY rev (3m)9.2%
Revenue NQ rev (1m)-0.3%
Revenue NQ rev (3m)-3.69%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)3.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.63 | ||
| Fwd PE | N/A | ||
| P/S | 0.55 | ||
| P/FCF | 2.96 | ||
| P/OCF | 2.59 | ||
| P/B | 1.83 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.34 |
EPS(TTM)0.19
EY7.34%
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.88
FCFY33.81%
OCF(TTM)1
OCFY38.58%
SpS4.68
BVpS1.42
TBVpS-1.55
PEG (NY)0.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.44% | ||
| ROE | 10.76% | ||
| ROCE | 18.88% | ||
| ROIC | 13.6% | ||
| ROICexc | 15.21% | ||
| ROICexgc | 569.19% | ||
| OM | 13.73% | ||
| PM (TTM) | 3.25% | ||
| GM | 52.45% | ||
| FCFM | 18.69% |
ROA(3y)-0.48%
ROA(5y)-5.11%
ROE(3y)-3.82%
ROE(5y)-38.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-2.29%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.67 | ||
| Debt/FCF | 1.95 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 46.7% | ||
| Cap/Sales | 2.64% | ||
| Interest Coverage | 3.16 | ||
| Cash Conversion | 110.07% | ||
| Profit Quality | 574.79% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.49 | ||
| Altman-Z | 0.83 |
F-Score5
WACC8.72%
ROIC/WACC1.56
Cap/Depr(3y)45.36%
Cap/Depr(5y)67.78%
Cap/Sales(3y)3.54%
Cap/Sales(5y)5.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
EPS Next Y651.46%
EPS Next 2Y-211.38%
EPS Next 3Y240.19%
EPS Next 5Y131.62%
Revenue 1Y (TTM)-5.34%
Revenue growth 3Y12.38%
Revenue growth 5Y27.27%
Sales Q2Q%18.96%
Revenue Next Year-4.03%
Revenue Next 2Y-5.31%
Revenue Next 3Y2.37%
Revenue Next 5Y6.71%
EBIT growth 1Y17.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.75%
EBIT Next 3Y27.04%
EBIT Next 5Y36.65%
FCF growth 1Y706.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1632.13%
OCF growth 3Y54.85%
OCF growth 5YN/A